COVID-19: how to tackle vaccine hesitancy among BAME groups

In silico post-hoc analysis of a clinically tested recombinant West Nile virus envelope protein vaccine.

Reiné J. et al, (2026), Comput Biol Chem, 122

Maternal views on RSV vaccination in the UK's second season.

O'Hagan S. et al, (2026), Lancet Infect Dis, 26, e209 - e211

Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned.

Yusuf S. et al, (2026), Lancet Infect Dis, 26, e259 - e267

Securing the future of immunisation: ESCMID's vision.

Ramasamy MN. et al, (2026), Clin Microbiol Infect, 32, 516 - 518

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

Weight CM. et al, (2026), J Infect Dis

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Turan G. et al, (2026), Vaccines (Basel), 14

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Bijukchhe SM. et al, (2026), Lancet Infect Dis

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Hausdorff WP. et al, (2026), Vaccine, 75

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

Advances in Alphavirus and Flavivirus Research II.

Kim YC. and Reyes-Sandoval A., (2026), Viruses, 18

Severe necrotizing soft tissue infections (SENSEI) study: Protocol for a multi-centered audit.

Yoshimura R. et al, (2026), JPRAS Open, 48, 331 - 336

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

The Epidemiology and Clinical Burden of Human Adenovirus Respiratory Infections Among Hospitalized Children Under 5 Years in Jordan.

Abu-Helalah M. et al, (2026), Pediatr Infect Dis J, 45, 229 - 235

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

Securing the future of immunisation: ESCMID’s vision

Ramasamy MN. et al, (2026), CMI Communications, 3, 105167 - 105167

MR-Pro-adrenomedullin (MR-proADM) and Host Immune Response Biomarkers Evaluation of procalcitonin-guided antibiotic duration in Children with Infection for Stratification of Effectiveness: the PRECISE Study

Waldron C-A. et al, (2026), Efficacy and Mechanism Evaluation, 1 - 46

Pneumococcal colonisation and mucosal immunity in adults with asthma following experimental human challenge

Reiné J. et al, (2026), BMJ Immunology, 1, e000012 - e000012

Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland.

O'Hagan S. et al, (2026), Arch Dis Child

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

Search results

Showing results for